The estimated Net Worth of Geoffrey M Duyk is at least $372 mil dollars as of 14 February 2017. Geoffrey Duyk owns over 58,167 units of Amyris Inc stock worth over $2,344 and over the last 21 years he sold AMRS stock worth over $277,131. In addition, he makes $92,855 as Independent Interim Chairman of the Board at Amyris Inc.
Sign up
Geoffrey Duyk AMRS stock SEC Form 4 insiders trading
Geoffrey has made over 5 trades of the Amyris Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he exercised 58,167 units of AMRS stock worth $778,274 on 14 February 2017.
The largest trade he's ever made was exercising 58,167 units of Amyris Inc stock on 14 February 2017 worth over $778,274. On average, Geoffrey trades about 2,665 units every 140 days since 2003. As of 14 February 2017 he still owns at least 46,870 units of Amyris Inc stock.
You can see the complete history of Geoffrey Duyk stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Geoffrey Duyk biography
Dr. Geoffrey M. Duyk M.D. Ph.D. serves as Independent Interim Chairman of the Board of the Company. Dr. Duyk previously served on the Board from May 2006 to May 2011. Dr. Duyk is a partner of Circularis Partners LP, a technology focused investment firm. Previously, Dr. Duyk served as a partner and managing director of TPG Alternative & Renewable Technologies, a technology focused investment firm (together with its affiliates, “TPG”), from 2004 to 2017. Prior to TPG, he served on the board of directors and was President of Research and Development at Exelixis, Inc., a biopharmaceutical company focusing on drug discovery, from 1996 to 2003. Prior to Exelixis, Dr. Duyk was Vice President of Genomics and one of the founding scientific staff at Millennium Pharmaceuticals, from 1993 to 1996. Before that, Dr. Duyk was an Assistant Professor at Harvard Medical School in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute. Dr. Duyk currently serves on the boards of directors of: Anuvia Plant Nutrients; Concentric Ag Corporation (formerly Inocucor Technologies, Inc.); and ReGen Holdings Limited as well as on the nonprofit Case Western Reserve University Board of Trustees. Dr. Duyk is also a member of the Institute Board of Directors of the Moffitt Cancer Center where he chairs the Research and Development committee. Dr. Duyk serves as a member of Scientific Advisory Boards for HudsonAlpha, and Lawrence Berkeley National Laboratory (DOE). Previously, Dr. Duyk served as a member of Scientific Advisory Boards for Bayer CropSciences, The Jackson Labs as well as numerous NIH advisory committees. He served on the board of directors of Beta Renewables from 2011 to 2017, Elevance Renewable Sciences from 2007 to 2018, The American Society of Human Genetics (nonprofit) from 2012 to 2018, EPIRUS Biopharmaceuticals, Inc. from July 2014 to July 2016, Galleon Pharmaceuticals, Inc. from 2007 to 2016, Genomatica, Inc. from 2012 to 2017, Karos Pharmaceuticals, Inc. from 2010 to 2015.
What is the salary of Geoffrey Duyk?
As the Independent Interim Chairman of the Board of Amyris Inc, the total compensation of Geoffrey Duyk at Amyris Inc is $92,855. There are 8 executives at Amyris Inc getting paid more, with John G. Melo having the highest compensation of $1,344,913.
How old is Geoffrey Duyk?
Geoffrey Duyk is 60, he's been the Independent Interim Chairman of the Board of Amyris Inc since 2014. There are 7 older and 13 younger executives at Amyris Inc. The oldest executive at Amyris Inc is Patrick Yang, 72, who is the Independent Director.
What's Geoffrey Duyk's mailing address?
Geoffrey's mailing address filed with the SEC is C/O AMYRIS, INC., 5885 HOLLIS STREET, SUITE 100, EMERYVILLE, CA, 94608.
Insiders trading at Amyris Inc
Over the last 14 years, insiders at Amyris Inc have traded over $118,642,007 worth of Amyris Inc stock and bought 100,049,915 units worth $258,812,433 . The most active insiders traders include Gas & Power Usa, Sas Total, L John Doerr, ePhilippe Boisseau. On average, Amyris Inc executives and independent directors trade stock every 25 days with the average trade being worth of $65,903. The most recent stock trade was executed by Hermanus Kieftenbeld on 2 June 2023, trading 20,999 units of AMRS stock currently worth $19,949.
What does Amyris Inc do?
amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. the company is delivering its no compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. more information about the company is available at www.amyris.com.
What does Amyris Inc's logo look like?
Complete history of Geoffrey Duyk stock trades at Aerie Pharmaceuticals Inc, Amyris Inc, Cardiovascular Systems, eExelixis Inc
Amyris Inc executives and stock owners
Amyris Inc executives and other stock owners filed with the SEC include:
-
John G. Melo,
Pres, CEO & Director -
John Melo,
President, Chief Executive Officer, Director -
Nicole Kelsey,
General Counsel, Secretary -
Eduardo Alvarez,
Chief Operating Officer -
Hermanus Kieftenbeld,
CFO & Chief Admin. Officer -
Eduardo Alvarez,
Chief Operating Officer -
Kathleen Valiasek,
Chief Business Officer -
Nicole Kelsey,
Gen. Counsel & Sec. -
Geoffrey Duyk,
Independent Interim Chairman of the Board -
Carole Piwnica,
Independent Director -
Steven Mills,
Independent Director -
John Doerr,
Independent Director -
Patrick Yang,
Independent Director -
Frank Kung,
Independent Director -
Philip Eykerman,
Director -
James McCann,
Independent Director -
Christoph Goppelsroeder,
Director -
Lisa Qi,
Independent Director -
Peter DeNardo,
Director, Investor Relations and Corporate Communications -
Julie Washington,
Director -
Sheila Pollak,
Chief Marketing Officer - Biossance -
Han Kieftenbeld,
Chief Financial Officer -
Jim Iacoponi,
Sr. VP of Nutrition Ingredients -
Caroline Hadfield,
Pres of Aprinnova -
Charles Kraft,
Sr. VP of Global Manufacturing & Process Devel. -
Christine Ofori,
Chief People Officer -
Anthony Hughes,
Chief Accounting Officer -
(Mauritius) Pte Ltd Cairnhi...,
-
Gas & Power Usa, Sas Total,
Director -
Joel Cherry,
President of R&D -
L John Doerr Ann Howland Va...,
-
Fernando De Castro Reinach,
Director -
Abraham Klaeijsen,
Director -
Thani Sheikh Abdullah Bin K...,
Director -
R Neil Williams,
Director -
Hermanus Kieftenbeld,
CFO AND INTERIM CEO -
Ana Dutra,
-
International B.V.Koninklij...,
-
Tina Maloney,
Chief Accounting Officer -
Raffinage Chimie Total,
Director -
James Young Richardson,
SVP, Vert Markets and Sales Op -
Nicholas Khadder,
General Counsel and Secretary -
Philippe Boisseau,
Director -
Mary Margaret Hastings Geor...,
Director -
Raffi Asadorian,
Chief Financial Officer -
(Mauritius) Pte Ltd Cairnhi...,
-
Ralph Alexander,
Director -
Jeryl L Hilleman,
Chief Financial Officer -
Perkins Caufield & Byers Xi...,
10% owner -
Peter Boynton,
Chief Commercial Officer -
Jefferson Lievense,
SVP, Process Dev. & Mfg. -
Keith Kinkead Reiling,
Director -
Xii Associates, Llc Kpcb,
10% owner -
Xii Founders Fund, Llc Kpcb,
10% owner -
Mario Portela,
Chief Operating Officer -
Tamara Tompkins,
SVP, Gen??l Counsel & Sec??ty -
Patrick Pichette,
Director -
Ventures Ii, L.P.Khosla Ven...,
-
Karen Weaver,
Principal Accounting Officer -
Neil Renninger,
Chief Technical Officer -
Samir Kaul,
Director -
(Mauritius) Pte Ltd Temasek...,
-
Arthur D Levinson,
Director -
Gary Loeb,
SVP, Gen'l Counsel & Secretary -
Paulo Sergio De Oliveira Diniz,
CEO, Amyris Brasil S.A. -
Susanna Mcferson,
CHIEF BUSINESS OFFICER -
Nam Hai Dr Chua,
Director -
Anthony Hughes,
CHIEF ACCOUNTING OFFICER -
Ryan Panchadsaram,
-
Elizabeth E. Dreyer,
CHIEF ACCOUNTING OFFICER -
L John Foris Ventures, Llc ...,